BioSpace News Archive

Compugen Ltd. announced that the Company will release its fourth quarter and full year 2018 financial results on Tuesday, February 26, 2019, before the U.S. financial markets open.

Ocugen, Inc. announced the U.S. Food and Drug Administration granted orphan drug designation for OCU400, Ocugen’s novel gene therapy, for the treatment of NR2E3 mutation-associated retinal degenerative disease.

Alkermes plc reported financial results for the year ended Dec. 31, 2018 and provided financial expectations for 2019.

Inovio Pharmaceuticals, Inc. announced the pricing of its offering of $65.0 million aggregate principal amount of 6.50% convertible senior notes due 2024.

Self Care Catalysts and the OncologyInformationService) are announcing a partnership to develop a patient-centered, real world dataset to drive advancements in cancer research.

Incyte Corporation (Nasdaq:INCY) today reports 2018 fourth quarter and year-end financial results, announces 2019 guidance and provides a status update on the Company’s development portfolio.

Premier Health Group, a Company focused on developing innovative approaches that combine human skill-based expertise with emerging technologies for the healthcare industry, is pleased to provide a corporate update.

Fujirebio Diagnostics, Inc., a consolidated subsidiary of Miraca Holdings Inc., has received Breakthrough Device Designation from the Center of Devices and Radiological Health of the U.S. Food and Drug Administration on January 3, 2019 for the Lumipulse G β-Amyloid Ratio quantitative in vitro diagnostic test.

Amorsa Therapeutics, Inc. announced that its patent application for deuterated norketamine and related NMDA receptor modulators was allowed for issuance as a new patent by the U.S. Patent and Trademark Office.

The Janssen Pharmaceutical Companies of Johnson & Johnson will present today at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) early results from the ongoing Phase 2 GALAHAD study evaluating niraparib,